Anglo-AstraZeneca, a Swedish pharmaceutical company, has agreed to collaborate with Absci, a U.S. AI biologics firm, to develop an antibody to fight cancer.
Anglo-Absci, a U.S. artificial intelligence (AI) biologics business, said in a statement on Sunday that Swedish drugmaker AstraZeneca has struck an agreement for up to $247 million with Absci to build an antibody to fight cancer.
According to the business, Absci’s collaboration with AstraZeneca aims for a zero-shot generative AI model aimed at producing new and enhanced antibody therapies. It did not specify what type of cancer they intended to target. Absci employs generative artificial intelligence to create the best drug candidates based on target affinity, safety, manufacturability, and other factors.
“We’re proud to work closely with AstraZeneca to leverage our AI to bring novel treatments to oncology patients,” Absci CEO Sean McClain stated.
According to a statement, the agreement includes an upfront fee for Absci, research and development funds, milestone payments, and royalties on any product sales.
Also read: Organizations should be driven based on people and processes instead of emphasizing technology
Do Follow: CIO News LinkedIn Account | CIO News Facebook | CIO News Youtube | CIO News Twitter
About us:
CIO News, a proprietary of Mercadeo, produces award-winning content and resources for IT leaders across any industry through print articles and recorded video interviews on topics in the technology sector such as Digital Transformation, Artificial Intelligence (AI), Machine Learning (ML), Cloud, Robotics, Cyber-security, Data, Analytics, SOC, SASE, among other technology topics.
